P. Martiat MD, PhD, A. Bosly MD, PhD, L. Noens MD, PhD, G. Verhoef MD, PhD, B. Houssa , P. Lacante MD
This study aimed to collect information on daily clinical use of dasatinib (Sprycel®) in Belgium, when used for treating patients with chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) with resistance or intolerance to prior therapies including imatinib.
We used an observational retrospective approach to collect data from 84 patients (72 CML and 12 Ph+ ALL) from 23 Belgian centres who received dasatinib in the period between October 1, 2007 and October 31, 2009.
The majority of patients had been diagnosed with chronic phase CML (69%). All patients had received prior treatment with imatinib before initiation of dasatinib. Main reasons for switching to dasatinib were development of resistance (65%) or intolerance (31%). In 89% of chronic and accelerated phase CML patients, dasatinib therapy induced complete haematological response (CHR). Major cytogenetic response (MCyR) was observed in 63% and 67% of chronic and accelerated phase patients, respectively.
This study population is representative for patients receiving dasatinib treatment in Belgium. Dasatinib was well tolerated and patient outcome confirmed dasatinib use has significant clinical value in the treatment of CML and Ph+ ALL patients with resistance or intolerance to prior imatinib therapy.